07:30

08:50

Registration & Breakfast

09:3009:30

Opening Speech by Leonard Sachs, Managing Director, Sachs Associates08:20

“Neurotherapeutics: Progress During an Era of Peace and Tranquility” by Harry Tracy, President, NI Research

Pharma Neurotherapeutics Pipeline: “The Challenges Ahead” Chaired by: Ginger Johnson, CEO, De�ned Health, a Cello Health business Panelists:Darryle Schoepp, VP Neuroscience Research, Merck & Co.Guy Seabrook, Vice President & Global Lead, Neuroscience External Innovation, Johnson & Johnson InnovationJennifer Laird, Senior Director, Search & Evaluation, Eli Lilly & Co.Michael Ehlers, Executive Vice President, R&D, BiogenMichael Gold, VP Neuroscience Development, AbbVie, Inc.

Partnering & DealMaking PanelCo-Chaired by:Bruce Leuchter, Managing Director, PJT PartnersSteve Dickman, CEO, CBT AdvisorsPanelists:Charles Bailey, Head of Search & Evaluation, Neurosciences, Global BD&L, Novartis Pharma AGDon Frail, SVP, Research, External Science, and Non-clinical and Translational Sciences, Allergan, Inc.Johannes Grosse, Director, Neuroscience Alliances, Takeda California, Inc.Laura Corradini, Deputy Global Head, BD&L CNS, Boehringer Ingelheim Pharma GmbH & Co. KGSha�que Virani, CEO in Residence, BridgeBio, LLC

08:30

10:10 Co�ee Break

10:25

Advances in Alzheimer’s and other Cognitive Disorders PanelChaired by:Ryan Westphal, Sr. Director Neuroscience External Innovation, Eli Lilly & Co.Panelists:Carlos Buesa, CEO, Oryzon Genomics SAElliot Goldstein, President & CEO, ProMIS™ Neurosciences, Inc.Isaac Veinbergs, Head of External Innovation, Neurosciences, Sano�Jonathan Lewis, CEO and Executive Chairman, Samus Therapeutics, Inc.Konrad Glund, CEO, Probiodrug AGSusan Catalano, CSO and Founder, Cognition Therapeutics, Inc.

PR Companies Track A - Room HeritageModerated by:

Katya Smirnyagina, Capricorn Venture Partners NV

10:25

10:45

11:05

11:25

11:45

Marinus Pharmaceuticals, Inc. [NASDAQ: MRNS]

Nexstim Plc [NXTMH:FH]

Cavion

Oryzon Genomics SA [BME:ORY]

Probiodrug AG [AMS:PBD]

11:05Introductory Speech to Neuropsychiatry and Pain Management Panel“Addressing the Su�ering of People with Neurologic, Psychiatric Su�ering and Chronic Pain”by Randall Stevens, CMO, Centrexion Therapeutics Corp.

New Approaches to Neuropsychiatry and Pain Management PanelCo-Chaired by:John Renger, Vice President, Head of Clinical Research and Translational Medicine, Purdue Pharma L.P.Raghuram Selvaraju, Managing Director, Senior Healthcare Analyst, Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLCPanelists:Deborah Rathjen, CEO & Managing Director, Bionomics Ltd.Jonathan Javitt, CEO, NeuroRx, Inc.Karl Johe, CSO, Neuralstem, Inc.Michael Scherz, Founder & CEO, Metys Pharmaceuticals AGSeth Lederman, CEO, Tonix Pharmaceuticals Holding Corp.

11:25

12:10

Medical Cannabis in Neuroscience PanelChaired by:Michael Farley, Director, Valor Management S.A.Panelists:Andrea Small-Howard, CSO, GB Sciences, Inc.Avtar Dhillon, Executive Chairman, Emerald Health Therapeutics, Inc.Catherine Jacobson, Director of Clinical Research, Tilray

12:05

12:25

ProMIS™ Neurosciences, Inc. [PMN:CN]

Click Therapeutics, Inc.

12:45 Networking Lunch

USA Marines’ Memorial Club, SF7 Jan 2018thFor BD&L and Investment in Therapeutics and TechnologyNEUROSCIENCE INNOVATION FORUM

Network/ID: MMC Ballroom WiFiPassword: LIVINGMEMORIAL1946

WIFI Info:

7:30

“New Insights from a Phase 2 Trial with Bryostatin in Advanced Alzheimer's Patients” by Daniel Alkon, President and CSO, Neurotrope Bioscience, Inc.13:30

Innovative Approaches to Parkinson's and Other Movement Disorders PanelCo-Chaired by:Kiran Reddy, Venture Partner, Clarus Ventures, LLCMurali Gopalakrishnan, Senior Director & Head, Search & Evaluation Neuroscience, AbbVie, Inc.Panelists:Andrew Hindman, Chief Business Development O�cer, Acorda Therapeutics, Inc.Brian Fiske, SVP, Research Programs, The Michael J. Fox FoundationtDamien McDevitt, SVP, Corporate Development, ACADIA Pharmaceuticals, Inc.Kees Been, CEO, Lysosomal Therapeutics, Inc.Kenneth Rhodes, CSO, Yumanity Therapeutics

13:50

12:45 Networking Lunch

PR Companies Track B - Room HeritageModerated by:

Beth Jacobs, Excellentia Global Partners

14:10

14:20

14:40

NoNO, Inc.

Metys Pharmaceuticals AG

15:00

Bonti

14:00

14:10

K-PAX Pharmaceuticals, Inc.

Cenna Biosciences, Inc.

Invisio Pharmaceuticals

Origenis GmbH

Sense Diagnostics, LLC

14:20

14:30

14:40

PR Companies Track D - Room HeritageModerated by:

Robert LeBoyer, Aegis Capital Corp.

15:00 AZTherapies, Inc.

15:20

15:40

15:50

Cognition Therapeutics, Inc.

KalGene Pharmaceuticals, Inc.

Flowonix Medical, Inc.

15:20

Emerald Health Therapeutics, Inc. [CVE: EMH]

15:40 Priavoid GmbH

15:50 Palisades Therapeutics

PR Companies Track E - Room CommandantsModerated by:

Raghuram Selvaraju, H.C. Wainwright & Co., LLC

14:35

15:10 Tonix Pharmaceuticals Holding Corp. [NASDAQ:TNXP]

15:30 Neuralstem, Inc. [NASDAQ:CUR]

15:50 Bionomics Ltd. [ASX:BNO]

16:10 NeuroRx, Inc.

16:30 Co�ee Break

16:45

Investor RoundtableChaired by:Beth Jacobs, Managing Partner, Excellentia Global PartnersPanelists:Barbara Tate, Venture Partner, SV Life SciencesChris Bennet, Instructor, Department of Psychiatry, Stanford UniversityDanny Talati, Director, New Business Development, Fortress Biotech, Inc.Jamil Beg, Principal, 5AM VenturesJay Olson, Analyst, Oppenheimer & Co., Inc.Manuel López-Figueroa, Venture Partner, Bay City Capital, LLC

17:30 Networking Reception

18:30 End of the NIF Forum

Current Trends in NeuroTech & Market Opportunities PanelCo-Chaired by:David Cassak, Editor-in-Chief, Innovation In Medtech, LLCStephen Levin, Managing Partner, Innovation In Medtech, LLCPanelists:David Klein, CEO, Click Therapeutics, Inc.Kevin Wasserstein, Founder and CEO, NeurotechnologyInnovations Translator, LLCMylea Charvat, CEO and Founder, Savonix, Inc.Steven Powell, CEO, Cambridge Cognition

NeuroActiva, Inc.

ASDERA

PR Companies Track C - Room RegimentalModerated By:

Florian Schödel, Philimmune LLC

13:50

15:30 Tal Medical